Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese

Archives of Dermatological Research

Volumn 297, Issue 7, 2006, Pages 329-332

  Hao, Jia Hu ^a   Ye, Dong Qing ^a   Zhang, Guo Qing ^a   Liu, Hui Hui ^a   Dai, Hong ^a   Huang, Fen ^a   Pan, Fa Ming ^a   Su, Hong ^a   Dong, Ma Xia ^b   Chen, Hong ^a   Wang, Qian ^a   Zhang, Xue Jun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Apoptosis; CD95 Antigens; Systemic lupus erythematosus; Systemic lupus erythematosus disease activity index

Indexed keywords

FAS ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; INFLAMMATION; KIDNEY; KIDNEY DISEASE; MALE; ORGAN INJURY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE; SCORING SYSTEM; SEROSA; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY;

ADOLESCENT; ADULT; ANTIGENS, CD95; APOPTOSIS; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEROSITIS; SEVERITY OF ILLNESS INDEX;

EID: 29044433364     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-005-0616-2     Document Type: Article

References (23)

1. Font J, Cervera R, Ramos-Casals M, Garcia-Carrasco M, Sents J, Herrero C, del Olmo JA, Darnell A, Ingelmo M (2004) Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 33:217-230
2. Bujan S, Ordi-Ros J, Paredes J, Mauri M, Matas L, Cortes J, Vilardell M (2003) Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann Rheum Dis 62859-62865
3. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, Hughes GR (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30:985-992
4. Al-Maini MH, Mountz JD, Al-Mohri HA, El-Ageb EM, Al-Riyami BM, Svenson KL, Zhou T, Richens ER (2000) Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus. Lupus 9:132-139
5. Bijl M, Horst G, Limburg PC, Kallenberg CG (2001) Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus 10:866-872
6. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H (1997) Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40:1126-1129
7. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762
8. van der Linden MW, van Lopik T, Aarden LA, Westendorp RG, Huizinga TW (2001) Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives. Ann Rheum Dis 60:237-241
9. Silvestris F, Williams RC, Calvani N, Grinello D, Tucci M, Cafforio P, Dammacco F (2002) Serum elevations of soluble Fas (CD95/apo-I) concur in deregulating T cell apoptosis during active lupus disease. Clin Exp Med 2:13-27
10. Courtney PA, Crockard AD, Williamson K, McConnell J, Kennedy RJ, Bell AL (1999) Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity. Lupus 8:508-513
11. van Lopik T, Bijl M, Hart M, Boeije L, Gesner T, Creasy AA, Kallenberg CG, Aarden LA, Smeenk RJ (1999) Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse. J Rheumatol 26:60-67
12. Rose LM, Latchman DS, Isenberg DA (1997) Elevated soluble fas production in SLE correlates with HLA status not with disease activity. Lupus 6:717-722
13. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630-640
15. Silvestris F, Grinello D, Tucci M, Cafforio P, Dammacco F (2003) Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus 12:8-14
16. Alecu M, Coman G, Alecu S (2000-2001) Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus. Rom J Intern Med 38-39:83-88
17. Bijl M, van Lopik T, Limburg PC, Spronk PE, Jaegers SM, Aarden LA, Smeenk RJ, Kallenberg GG (1998) Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?. J Autoimmun 11:457-463
18. Hamar P, Song E, Kokeny G, Chen A, Ouyang N, Lieberman J (2004) Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci USA 101:14883-14888, E-pub 2004 October 04
19. Ortiz A, Lorz C, Egido J (1999) New kids in the block: the role of FasL and Fas in kidney damage. J Nephrol 12:150-158
20. Schelling JR, Nkemere N, Kopp JB, Cleveland RP (1998) Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest 78(7):813-824
21. Kacprzyk F (2002) Serum level and urinary excretion of soluble Fas (sFas) in patients with primary glomerulopathies. Pol Arch Med Wewn 108:843-847
22. Jarad G, Lakhe-Reddy S, Blatnik J, Koepke M, Khan S, El-Meanawy MA, O'Connor AS, Sedor JR, Schelling JR (2004) Renal phenotype is exacerbated in Os and lpr double mutant mice. Kidney Int 66:1029-1035
23. Silva LM, Garcia AB, Donadi EA (2002) Increased lymphocyte death by neglect-apoptosis is associated with lymphopenia and autoantibodies in lupus patients presenting with neuropsychiatric manifestations. J Neurol 249:1048-1054